- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
BRAF N-Terminal Antibody RM308 / BRAF N-Terminus Antibody [clone RM308] (R20328)
Email: info@nsjbio.com
| Catalog No | Formulation | Size | Price (USD) | ||
|---|---|---|---|---|---|
|
R20328-0.1ML | Antibody in PBS with 50% glycerol, 1% BSA and 0.09% sodium azide | 100 ul | 439 |
| Availability | 1-3 business days |
| Species Reactivity | Human |
| Predicted Reactivity | Mouse |
| Format | Purified |
| Host | Rabbit |
| Clonality | Recombinant Rabbit Monoclonal |
| Isotype | Rabbit IgG |
| Clone Name | RM308 |
| Purity | Protein A purified from animal origin-free supernatant |
| UniProt | P15056 |
| Localization | Cytoplasmic |
| Applications | Immunohistochemistry (FFPE) : 1:200-1:500 Western Blot : 1:100-1:200 |
| Limitations | This BRAF N-Terminal Antibody RM308 / BRAF N-Terminus Antibody is available for research use only. |
|
Review this product on BioCompare and get a $20 Amazon gift card
|
Related Products
|
BRAF N-Terminal Antibody RM308 / BRAF N-Terminus Antibody detects the N-terminal region of BRAF, a serine/threonine protein kinase and member of the RAF family. BRAF functions within the RAS-RAF-MEK-ERK signaling pathway, transmitting signals from activated RAS proteins to MEK and ERK. This pathway regulates cellular proliferation, differentiation, survival and responses to extracellular growth signals.
The BRAF protein contains an N-terminal regulatory region and a C-terminal serine/threonine kinase domain. The N-terminal portion includes conserved regulatory elements involved in controlling BRAF activation and interactions with upstream signaling components. Recognition of this region differentiates a BRAF N-Terminus Antibody from reagents directed against other portions of the protein and can be useful when antibody epitope location is an important consideration in experimental design.
BRAF is extensively studied in cancer because activating alterations can produce sustained MAPK pathway signaling. The V600E substitution within the kinase domain is the best-known BRAF mutation and occurs in melanoma as well as thyroid, colorectal, lung and other cancers. Other BRAF alterations, including mutations, fusions and changes affecting regulatory regions, further illustrate the diverse mechanisms through which abnormal BRAF signaling can contribute to disease.
Clone RM308 is a recombinant rabbit monoclonal antibody generated against a peptide corresponding to residues near the N-terminus of human BRAF. Its defined N-terminal targeting provides a differentiated reagent for researchers examining BRAF expression and RAF-MAPK pathway biology.
For a general monoclonal reagent targeting BRAF, see our BRAF Antibody BRAF/1626 / B-Raf Kinase Antibody page. NSJ Bioreagents provides antibodies for research into RAF kinases and related signaling pathways. A BRAF N-Terminal Antibody provides a research tool for detecting BRAF and investigating its roles in MAPK signaling, cellular growth and cancer biology.
For a monoclonal reagent targeting BRAF, see our BRAF Antibody BRAF/1626 / B-Raf Kinase Antibody page.
The stated application concentrations are suggested starting points. Titration of the BRAF N-Terminal Antibody RM308 / BRAF N-Terminus Antibody may be required due to differences in protocols and secondary/substrate sensitivity.
A peptide corresponding to the residues near N-terminus of human B-raf was used as the immunogen for the recombinant BRAF N-Terminal Antibody RM308.
Store the BRAF N-Terminal Antibody RM308 at -20oC.
BRAF antibody, B-Raf antibody, BRAF1 antibody, B-RAF1 antibody, RAFB1 antibody, Serine/threonine-protein kinase B-Raf antibody, Proto-oncogene B-Raf antibody, NS7 antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.
Powered by Bioz
